The antibody against p24 capsid antigen increased as much as 64-fold in
some vaccinees while the antibody against gp120 surface antigen
increased up to eight-fold. P24 is a structural protein that makes up
most of the HIV viral core also known as the ‘capsid.’ High levels of p24
are present in the blood serum of newly infected individuals during the
short period between infection and seroconversion, making p24 antigen
assays useful in diagnosing primary HIV infection. A glycoprotein, gp120, is necessary for attachment to cell surface receptors and also allows for the HIV virus to enter cells.
,,,
Since the virus was characterized in 1983, pharmaceutical companies and
academic institutions around the world have attempted, yet consistently
failed, to develop a vaccine. What is unique about Kang’s vaccine is its
use of a killed-whole HIV-1, which is similar to the vaccines developed
for polio, influenza, and rabies. HIV-1 is also genetically engineered;
this raises its safety profile and the possibility of it being produced
in large quantities.
New HIV Vaccine Proves Successful In Phase 1 Human Trial
No comments:
Post a Comment